InvestorsHub Logo
Followers 1
Posts 24
Boards Moderated 0
Alias Born 02/12/2011

Re: None

Saturday, 11/19/2011 12:48:22 PM

Saturday, November 19, 2011 12:48:22 PM

Post# of 552
Even if the R/S goes thru, its not bad thing for this company as I believe its priced in already. They are doing it to acquire or merge with allozyne. It's not a usual .r/s. Two things you should consider, the current market cap of Pard and the people coming onboard, not to forget, a drug similar to biogen.Although we could be pleasantly surprised if there is more news and we get above a dollar without a reverse split.